Form SC 13G - Statement of acquisition of beneficial ownership by individuals

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

__________________________________________

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 11)* 

__________________________________________

Cumberland Pharmaceuticals Inc.

 _______________________________________

(Name of Issuer)

Common Stock 

__________________________________________

(Title of Class of Securities)

230770109

__________________________________________

(CUSIP Number)

December 31, 2023

__________________________________________ 

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)

o Rule 13d-1(c)

x Rule 13d-1(d)

 

*			The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

---

CUSIP No. 230770109

 

1						NAMES OF REPORTING PERSONS. A.J. Kazimi
2						CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) Not applicable   (a) o (b) o
3						SEC USE ONLY
4						CITIZENSHIP OR PLACE OF ORGANIZATION   United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:												5						SOLE VOTING POWER   5,721,267
												6						SHARED VOTING POWER   None
												7						SOLE DISPOSITIVE POWER   5,721,267
												8						SHARED DISPOSITIVE POWER   None
9						AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON   5,721,267
10						CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)   Not applicable   o
11						PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)   40.14%
12						TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)   IN

 

 

Page 2 of 5 pages

---

Item 1.

 

			(a)			Name of Issuer

 

						Cumberland Pharmaceuticals Inc.

 

			(b)			Address of Issuer's Principal Executive Offices

 

						1600 West End Avenue, Suite 1300, Nashville, TN 37203

Item 2.

 

			(a)			Name of Person Filing

 

						A.J. Kazimi

 

			(b)			Address of Principal Business Office or, if none, Residence

 

						1600 West End Avenue, Suite 1300, Nashville, TN 37203

 

			(c)			Citizenship

 

						United States

 

			(d)			Title of Class of Securities

 

						Common Stock

 

			(e)			CUSIP Number

 

						230770109

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

 

Item 4. Ownership.

 

			(a)			Amount beneficially owned:

 

						5,721,267

 

			(b)			Percent of class:

 

						40.14%

 

Page 3 of 5 pages

---

			(c)			Number of shares as to which the person has:

 

			(i)			Sole power to vote or to direct the vote

 

						5,721,267

 

			(ii)			Shared power to vote or to direct the vote

 

						None.

 

			(iii)			Sole power to dispose or to direct the disposition of

						5,721,267

 

			(iv)			Shared power to dispose or to direct the disposition of

 

						None.

Item 5. Ownership of Five Percent or Less of a Class

Not applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certification

Not applicable

 

Page 4 of 5 pages

---

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

			February 9, 2024
			Date
			/s/ A.J. Kazimi*
			Signature
			A.J. Kazimi, Chief Executive Officer
			Name/Title

 

* By: /s/ John Hamm, as attorney-in-fact, pursuant to a Power of Attorney dated June 10, 2021 and filed with the SEC on June 11, 2021.

 

Page 5 of 5 pages

---